- Report
- May 2024
- 133 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 133 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- October 2022
- 270 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- November 2023
- 115 Pages
United States
From €3579EUR$3,750USD£2,999GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2625EUR$2,750USD£2,199GBP
- Report
- January 2022
- 200 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- April 2018
United States
From €7630EUR$7,995USD£6,393GBP
Orencia is a biologic drug used to treat immune disorders, such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. It is a recombinant human monoclonal antibody that works by blocking the activity of a protein called TNF-alpha, which is involved in the inflammation process. Orencia is administered via subcutaneous injection and is available in both a prefilled syringe and a vial.
Orencia is a relatively new drug, having been approved by the US Food and Drug Administration in 2005. It is currently marketed by Bristol-Myers Squibb, and is available in the United States, Canada, Europe, and other countries.
The Orencia market is highly competitive, with several other biologic drugs available to treat immune disorders. These include Humira, Enbrel, Remicade, and Simponi. In addition, there are several generic versions of Orencia available in some countries.
Companies in the Orencia market include Bristol-Myers Squibb, AbbVie, Pfizer, Merck, and Janssen Pharmaceuticals. Show Less Read more